ArticleAbdominal radiology (New York)2026
Optimization of contrast medium dosing using a body surface area-based protocol for preoperative CT colonography-angiography.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate whether a body surface area (BSA)-based adjusted body weight (AdBW) protocol stabilizes vascular and hepatic parenchymal enhancement during preoperative CT colonography-angiography (CTC-A).
methodsThis retrospective single-center study included 221 consecutive patients with colorectal cancer who underwent preoperative CTC-A between January 2024 and March 2025. Examinations used either a total body weight (TBW)-based iodine protocol (600 mg I/kg; n = 113) or a BSA-based AdBW protocol (21.74 g I/m
resultsRegression slopes for the TBW and AdBW protocols were 2.96 versus 0.13 HU/kg for the AA, 3.98 versus -0.39 HU/kg for the SMA, 4.53 versus 0.22 HU/kg for the IMA, and 0.42 versus -0.06 HU/kg for hepatic parenchyma, respectively. The AdBW protocol reduced body weight dependency for all enhancement parameters. In stratified analyses, vascular attenuation remained stable across all body weight groups with AdBW dosing (all p > 0.05). Hepatic enhancement was also more consistent, with median values maintained at approximately 57.5-61.1 HU. Qualitative assessment showed that vascular visualization and liver metastasis conspicuity remained clinically acceptable with the AdBW protocol.
conclusionBSA-based AdBW dosing reduced body habitus-dependent variability in vascular and hepatic enhancement during preoperative CTC-A.
Indexed as
Identifiers
42517900What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.